Markets

ImmunityBio Treats First Patient In Europe With ANKTIVA In Combination With Bacillus Calmette-Guérin

Nov 4, 2026 · 08:09 AM ET· updated 1h ago

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus

Why It Matters

ImmunityBio started treating patients in Europe with a new cancer medicine. When a company tests drugs in new places, it shows the medicine is moving forward in the world.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IBRX8.33

+0.04 (+0.48%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.